^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Acute Lymphocytic Leukemia
    Drug:Graspa (eryaspase) (Asparagine depleter)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Erytech Pharma Press Release
    Title:

    ERYTECH GRANTED U.S. FDA FAST TRACK DESIGNATION FOR ERYASPASE IN HYPERSENSITIVE ALL

    Published date:
    07/29/2021
    Excerpt:
    ERYTECH Pharma (Nasdaq & Euronext: ERYP)...announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase (PEG-ASNase).